마이크로바이옴과 암 면역 치료
Microbiome and Cancer Immunotherapy
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Immune checkpoint inhibitors (ICIs) have achieved promising clinical results in cancer treatment over the past decade. However, the efficacy of ICIs is less than 30% in most tumor types, and studies are underway to identify the predictive factors responsive to ICIs. More than 1,000 species of microorganisms live in the human body, and the second human genome project, The Human Microbiome Project, has been conducted to understand human diseases through interactions with microbes. As the microbiome project has progressed, many studies have reported on the association between microorganisms and human diseases, including preclinical and clinical studies on the relationship between ICIs and the microbiome. Therefore, in this manuscript, the relationship between the microbiome and cancer, especially the effectiveness of ICIs, is reviewed.
Abstract
Immune checkpoint inhibitors (ICIs) have achieved promising clinical results in cancer treatment over the past decade. However, the efficacy of ICIs is less than 30% in most tumor types, and studies are underway to identify the predictive factors responsive to ICIs. More than 1,000 species of microorganisms live in the human body, and the second human genome project, The Human Microbiome Project, has been conducted to understand human diseases through interactions with microbes. As the microbiome project has progressed, many studies have reported on the association between microorganisms and human diseases, including preclinical and clinical studies on the relationship between ICIs and the microbiome. Therefore, in this manuscript, the relationship between the microbiome and cancer, especially the effectiveness of ICIs, is reviewed.
참고문헌 (31)
- Robert C, "A decade of immune-checkpoint inhibitors in cancer therapy", Nat Commun, 11, pp.3801~ (2020)
- Bai R, "Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors", Biomark Res, 8, pp.34~ (2020)
- Turnbaugh PJ, "The human microbiome project", Nature, 449, pp.804~810 (2007)
- Helmink BA, "The microbiome, cancer, and cancer therapy", Nat Med, 25, pp.377~388 (2019)
- Coley WB., "The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893", Clin Orthop Relat Res., 262, pp.3~11 (1991)
- Ribas A, "Tumor immunotherapy directed at PD-1", N Engl J Med, 366, pp.2517~2519 (2012)
- Naidoo J, "Toxicities of the anti-PD-1and anti-PD-L1 immune checkpoint antibodies", Ann Oncol, 26, pp.2375~2391 (2015)
- Arnaud-Coffin P, "A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors", Int J Cancer, 145, pp.639~648 (2019)
- Tray N, "Predictive biomarkers for checkpoint immunotherapy : current status and challenges for clinical application", Cancer Immunol Res, 6, pp.1122~1128 (2018)
- Reck M, "Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer", N Engl J Med, 375, pp.1823~1833 (2016)
- Le DT, "PD-1 blockade in tumors with mismatch-repair deficiency", N Engl J Med, 372, pp.2509~2520 (2015)
- Overman MJ, "Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer(CheckMate 142) : an open-label, multicentre, phase 2 study", Lancet Oncol, 18, pp.1182~1191 (2017)
- Klempner SJ, "Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence", Oncologist, 25, pp.e147~e159 (2020)
- Grice EA, "The human microbiome : our second genome", Annu Rev Genomics Hum Genet, 13, pp.151~170 (2012)
- Blumberg R, "Microbiota, disease, and back to health : a metastable journey", Sci Transl Med, 4, pp.137rv7~ (2012)
- Di Domenico EG, "Biofilm producing Salmonella typhi : chronic colonization and development of gallbladder cancer", Int J Mol Sci, 18, pp.1887~ (2017)
- Wang F, "Helicobacter pylori-induced gastric inflammation and gastric cancer", Cancer Lett, 345, pp.196~202 (2014)
- Yang Y, "Novel insights into microbiome in colitis and colorectal cancer", Curr Opin Gastroenterol, 33, pp.422~427 (2017)
- Kostic AD, "Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment", Cell Host Microbe, 14, pp.207~215 (2013)
- Huang Y, "Identification of helicobacter species in human liver samples from patients with primary hepatocellular carcinoma", J Clin Pathol, 57, pp.1273~1277 (2004)
- Rocha M, "Association of Helicobacter species with hepatitis C cirrhosis with or without hepatocellular carcinoma", Gut, 54, pp.396~401 (2005)
- Grąt M, "Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis", Transplant Proc, 48, pp.1687~1691 (2016)
- Yoshimoto S, "Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome", Nature, 499, pp.97~101 (2013)
- Lee SH, "Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions", Lung Cancer, 102, pp.89~95 (2016)
- Yu G, "Characterizing human lung tissue microbiota and its relationship to epidemiological and clinical features", Genome Biol, 17, pp.163~ (2016)
- Sivan A, "Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy", Science, 350, pp.1084~1089 (2015)
- Matson V, "The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients", Science, 359, pp.104~108 (2018)
- Gopalakrishnan V, "Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients", Science, 359, pp.97~103 (2018)
- Van Nood E, "Duodenal infusion of donor feces for recurrent Clostridium difficile", N Engl J Med, 368, pp.407~415 (2013)
- Baruch EN, "Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients", Science, 371, pp.602~609 (2021)
- Davar D, "Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients", Science, 371, pp.595~602 (2021)